|
|
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Number of employees : 675 people.
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | Novel Medicines | 90.27 | 100% | 6.87 | 100% | -92.39% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 90.27 | 100% | 6.87 | 100% | -92.39% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
52,047,696 |
51,071,858 |
98.1% |
3,033 |
0.0% |
98.1% |
|
|
|
| Name | Equities | % | | Fidelity Management & Research Co. LLC | 7,732,540 |
14.9% | | The Vanguard Group, Inc. | 4,658,897 |
8.96% | | T. Rowe Price Associates, Inc. (Investment Management) | 2,819,052 |
5.42% | | D. E. Shaw & Co. LP | 2,122,156 |
4.08% | | Great Point Partners LLC | 2,102,368 |
4.05% | | Citadel Advisors LLC | 1,763,613 |
3.39% | | Invesco Advisers, Inc. | 1,705,278 |
3.28% | | SSgA Funds Management, Inc. | 1,488,399 |
2.86% | | Janus Capital Management LLC | 1,459,676 |
2.81% | | OppenheimerFunds, Inc. | 1,443,145 |
2.78% |
|
| Company contact information |
|
SAGE Therapeutics, Inc. 215 1st Street Cambridge, MA 02142 Phone : +1.617.299.8380 Fax : +1.617.299.8379 Web : http://www.sagerx.com |
|
|
Sector Biotechnology & Medical Research - NEC
| | 1st jan. | Capitalization (M$) |
 |
 | SAGE THERAPEUTICS, INC. | 8.01% | 3 965 |
| | | |
|
 | LONZA GROUP AG | 63.36% | 47 043 |
| MODERNA, INC. | 399.03% | 38 625 |
 | CELLTRION, INC. | 66.30% | 35 570 |
| IQVIA HOLDINGS INC. | 9.88% | 32 549 |
| SEAGEN INC. | 51.77% | 31 267 |
| IMMUNOMEDICS, INC. | 315.22% | 20 324 |
| INCYTE CORPORATION | -6.17% | 17 942 |
| ALNYLAM PHARMACEUTICALS, INC. | 8.27% | 14 488 |
 | HANGZHOU TIGERMED CONSULTING CO.,LTD | 85.76% | 13 472 |
| PPD, INC. | 0.00% | 11 801 |
| BIO-TECHNE CORPORATION | 38.90% | 11 772 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 52.23% | 11 567 |
| QIAGEN N.V. | 39.67% | 10 790 |
| PHARMARON BEIJING CO., LTD. | 92.08% | 10 351 |
| ICON PUBLIC LIMITED COMPANY | 10.13% | 10 010 |
| ACADIA PHARMACEUTICALS INC. | 24.99% | 8 516 |
 | GALAPAGOS NV | -43.51% | 8 164 |
| CRISPR THERAPEUTICS AG | 80.12% | 7 751 |
| PRA HEALTH SCIENCES, INC. | 0.98% | 7 200 |
| IONIS PHARMACEUTICALS, INC. | -18.66% | 6 871 |
Connections : Sage Therapeutics, Inc. |
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
